Cargando…
Breast cancer screening in high risk women
Women who are at a significantly raised risk of developing breast cancer should be assessed by a medical geneticist to confirm their history, counselled as to appropriate management and offered breast screening. Currently mammography with magnetic resonance imaging is considered the optimal method o...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
e-Med
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582500/ https://www.ncbi.nlm.nih.gov/pubmed/18852075 http://dx.doi.org/10.1102/1470-7330.2008.9002 |
_version_ | 1782160675309617152 |
---|---|
author | Gilbert, Fiona J. |
author_facet | Gilbert, Fiona J. |
author_sort | Gilbert, Fiona J. |
collection | PubMed |
description | Women who are at a significantly raised risk of developing breast cancer should be assessed by a medical geneticist to confirm their history, counselled as to appropriate management and offered breast screening. Currently mammography with magnetic resonance imaging is considered the optimal method of early detection of breast cancer in these women. While there is no evidence of mortality benefit there is evidence from surrogate markers that this intervention is worthwhile and cost effective. National recommendations have been produced by the National Institute of Clinical Excellence in the UK and also by the American Cancer Society. |
format | Text |
id | pubmed-2582500 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | e-Med |
record_format | MEDLINE/PubMed |
spelling | pubmed-25825002010-10-04 Breast cancer screening in high risk women Gilbert, Fiona J. Cancer Imaging Focus on: Breast Cancer Women who are at a significantly raised risk of developing breast cancer should be assessed by a medical geneticist to confirm their history, counselled as to appropriate management and offered breast screening. Currently mammography with magnetic resonance imaging is considered the optimal method of early detection of breast cancer in these women. While there is no evidence of mortality benefit there is evidence from surrogate markers that this intervention is worthwhile and cost effective. National recommendations have been produced by the National Institute of Clinical Excellence in the UK and also by the American Cancer Society. e-Med 2008-10-04 /pmc/articles/PMC2582500/ /pubmed/18852075 http://dx.doi.org/10.1102/1470-7330.2008.9002 Text en © 2008 International Cancer Imaging Society |
spellingShingle | Focus on: Breast Cancer Gilbert, Fiona J. Breast cancer screening in high risk women |
title | Breast cancer screening in high risk women |
title_full | Breast cancer screening in high risk women |
title_fullStr | Breast cancer screening in high risk women |
title_full_unstemmed | Breast cancer screening in high risk women |
title_short | Breast cancer screening in high risk women |
title_sort | breast cancer screening in high risk women |
topic | Focus on: Breast Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582500/ https://www.ncbi.nlm.nih.gov/pubmed/18852075 http://dx.doi.org/10.1102/1470-7330.2008.9002 |
work_keys_str_mv | AT gilbertfionaj breastcancerscreeninginhighriskwomen |